Atypical Hemolytic-Uremic Syndrome During Pregnancy. Present and Latest Results of Treatment

Abstract

Atypical hemolytic-uremic syndrome being referred to autoimmune diseases appears to be one of the most severe forms of thrombosis and microangiopathy. Difficulties in diagnosis cause a delay in pathogenetic therapy, which causes a high maternal mortality rate. Pathogenetic therapy with eculizumab, suppressing the terminal activity of complement, may contribute to the recovery of blood coagulation properties, but the long-term prognosis for chronic renal failure remains unfavorable. The article deals with a clinical case confirming this conclusion.